<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>27(3)</volume><submitter>Wang L</submitter><pubmed_abstract>Hemocompatibility is critical for intravenous hemoglobin-based oxygen carriers (HBOCs). We evaluated the hemocompatibility of polyethylene glycol-conjugated bovine hemoglobin (PEG-bHb) to facilitate its optimization and clinical translation. PEG-bHb was synthesized and characterized. In vitro hemocompatibility was assessed by incubating blood components with PEG-bHb (2.5-40 mg/mL), evaluating erythrocyte morphology/function, coagulation, complement activation, and leu kocyte phagocytosis. In vivo assessments in Wistar rats injecting PEG-bHb (50-100 mg/kg) included erythrocyte function, coagulation, complement activation, and histopathology. PEG-bHb exhibited increased hydrodynamic diameter, unaltered zeta potential, elevated colloidal osmotic pressure (COP) and viscosity, alongside a decre</pubmed_abstract><journal>International journal of molecular sciences</journal><pagination>1262</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12898566</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Hemocompatibility Evaluation of PEGylated Bovine Hemoglobin.</pubmed_title><pmcid>PMC12898566</pmcid><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Zeng Q</pubmed_authors><pubmed_authors>Tao S</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>You G</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhou H</pubmed_authors><pubmed_authors>Yu H</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hemocompatibility Evaluation of PEGylated Bovine Hemoglobin.</name><description>Hemocompatibility is critical for intravenous hemoglobin-based oxygen carriers (HBOCs). We evaluated the hemocompatibility of polyethylene glycol-conjugated bovine hemoglobin (PEG-bHb) to facilitate its optimization and clinical translation. PEG-bHb was synthesized and characterized. In vitro hemocompatibility was assessed by incubating blood components with PEG-bHb (2.5-40 mg/mL), evaluating erythrocyte morphology/function, coagulation, complement activation, and leu kocyte phagocytosis. In vivo assessments in Wistar rats injecting PEG-bHb (50-100 mg/kg) included erythrocyte function, coagulation, complement activation, and histopathology. PEG-bHb exhibited increased hydrodynamic diameter, unaltered zeta potential, elevated colloidal osmotic pressure (COP) and viscosity, alongside a decre</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-07-07T03:10:36.129Z</modification><creation>2026-07-07T03:09:36.87Z</creation></dates><accession>S-EPMC12898566</accession><cross_references><pubmed>41683691</pubmed><doi>10.3390/ijms27031262</doi></cross_references></HashMap>